Bharat Biotech's Covaxin gets Subject Expert Committee (SEC) approval for emergency use

A day after the Subject Expert Committee gave a go-ahead to SII, Oxford-Astrazeneca vaccine candidate-Covishield, the expert panel today recommended Bharat Biotech’s Covaxin too for restricted emergency use, government sources have confirmed. The Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.


Read More   Ericsson stresses early bird 5G advantage

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.